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IdentIfy chf and coPd PaItIents at hIgh RIsk of hosPItalIzatIon: 
UsIng PRedIctIve analytIcs foR PatIent oUtReach
Wang Q.C., Higgins S.L., Chawla R., Nigam S.
Independence Blue Cross, Philadelphia, PA, USA
Objectives: To develop predictive models to identify CHF and COPD patients at 
high risk of hospitalization within the next 6 months to be used for case manage-
ment outreach. DAtA sOurces: Data were extracted from several sources and 
included patient diagnoses, service utilization, lab data, and medication adherence 
from a large health insurance claims database, ZIP code level demographic data 
from the U.S. Census, patient level illness burden scores, medical episode group-
ers, Experian consumer and credit information, and call data between patients 
and customer service representatives. stuDy POPulAtiOn: All commercial and 
Medicare members who were identified with congestive heart failure (CHF) and 
chronic obstructive pulmonary disease (COPD) and who were continuously enrolled 
for at least 6 months during the model development period and 6 months during 
the predictive period were included. MethODs: Using three years of historical 
data from 2010 to 2012 and admissions between January and June 2013 as the target 
variable, the data were randomly split in half as training and validation data. The 
training data were used to build the predictive model. The validation data were used 
to evaluate model performance. Several algorithms were utilized to build predictive 
models: logistic regression, neural networks, and decision trees. The models were 
evaluated based on the lift chart and/or area under the ROC curve. The selected 
models were used to score data and predict future admissions. results: The key 
factors predicting admissions in the next 6 months included length of time identi-
fied with CHF and COPD, medication adherence, prior admissions, recent specialist 
visits, having had a customer call that mentioned ‘hospital bed/hospital stay’, and 
being on oxygen (for COPD). cOnclusiOns: Four models of predicting patients 
at highest risk of admission have been developed, which were used to generate a 
list of patients with high probability of admission for case management outreach.
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an analytIcal Method foR estIMatIng the boUndaRIes of an 
IncReMental cost-effectIveness RatIo
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1The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2MSD.K.K. & HTA and 
Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan
Objectives: To develop an analytical method which quantifies the reasonable 
limits for any incremental cost-effectiveness ratio (ICER) defined by the slope of a 
line connecting two points on the cost-benefit plane. MethODs: Assume that the 
ICER of a target technology vs. its comparator is defined with two points at each of 
which a pair of cost and benefit is given on the C(cost)-E(benefit) plane. In order to 
find a cost-benefit function connecting the two points, an analytical method was 
developed by means of curve-fitting technique with exponential and quadratic mod-
eling. The resultant cost-benefit function was further analytically expanded to the 
derivative, dC/dE, we call it “tangent limit”. Example calculations of the tangent lim-
its were conducted for each model. results: The analytical development resulted 
in the following equations of the cost-benefit function and the derivative for each 
modeling: C = Exp((E - p)/q) and dC/dE = (1/q) Exp((E - p)/q) for exponential model, 
whilst C = (1/q)E2 - p/q and dC/dE = 2E/q for quadratic model, where p and q are 
parameters determined by costs and benefits of the target technology and its com-
parator. Applying the equations for two hypothetical points, (7.6 QALY, US$100,000) 
and (8.6 QALY, US$150,000), we found that the ICER of 50 bounds with the lower and 
the upper limits, respectively, 40.6 and 60.8 US$(x1000)/QALY for exponential model, 
and as well, 46.9 and 53.1 for quadratic model. Those estimates were not so much 
different as the limits of 43.9 and 65.8 for the ICER of 54.1, obtained by the regression 
analysis presented in the ISPOR New Orleans 2013. cOnclusiOns: Our approach 
can offer a simple and science-based method to estimate boundaries for any ICER. 
It would be useful for negotiations and decisions in value-based pricing in which a 
range of ICER must be considered beyond a single threshold ratio.
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Objectives: High-dimensional propensity score (PS) methods have been used in 
health care claims data to improve control of confounding by adjusting for a large 
number of covariates that may be proxies for unobserved factors. We have previ-
ously shown that PS models are biased for non-linear link functions when con-
founders were included. We conducted a simulation study to understand whether 
inclusion of covariates that are not confounders may also bias the association by 
estimating Monte Carlo mean bias, relative efficiency (RE) and coverage probability 
(CP) of log odds ratios when covariates only related to the exposure or only related 
to the outcome were included. MethODs: We conducted 1000 Monte Carlo simula-
tions, and estimated effect of exposure using logistic regression models. The propen-
sity score was included in the logistic model as a linear predictor or as a smoothed 
covariate using restricted cubic splines. Simulations were conducted for scenarios 
including 5, 15, and 25 covariates. results: Using the PS with 25 covariates related 
only to the binary exposure, Monte Carlo bias, standard error (SE), RE and CP were 
-0.002, 0.015, 1.34, and 0.94 when the PS was included as a smoothed covariate, and 
–0.002, 0.015, 1.31, and 0.94 when the PS was included as a linear covariate. The 
bias, SE, RE and CP for 25 covariates related to the binary outcome were 0.307, 0.096, 
21.6, and 0 when the PS was included as a linear covariate. Bias tended to increase 
with more covariates. cOnclusiOns: We observed minimal bias when using PS 
models where covariates were related only to the exposure, but substantial bias 
when the covariates were related to the outcome. PS models may not be appropriate 
for logistic models because these models do not adequately deal with errors in the 
outcome due to the covariate.
Objectives: Genetic programming is an Evolutionary Computing technique, 
inspired by biological evolution, capable of discovering complex non-linear pat-
terns in large datasets. Despite the potential advantages of genetic programming 
over standard statistical methods, its applications to survival analysis are at best 
rare, primarily because of the difficulty in handling censored data. The aim of this 
study was to demonstrate the utility of genetic programming for the automatic 
development of clinical prediction models using cardiovascular disease as a case 
study. MethODs: We compared genetic programming and the commonly used 
Cox regression technique in the development of a cardiovascular risk score using 
data from the SMART study, a prospective cohort study designed to identify predic-
tors of future cardiovascular events in patients with symptomatic cardiovascular 
disease. The primary outcome was any cardiovascular event, comprising cardiovas-
cular death and non-fatal stroke and myocardial infarction. The predictive ability 
of the model was assessed in terms of discrimination and calibration. results: 
3,873 patients were enrolled in the study 1996–2006, aged 19–82 years and with 
460 cardiovascular events. The discrimination of both models was comparable; the 
C-index of the genetic programming model being smaller (0.65; 95% CI: 0.63–0.66) 
but not significantly different from that of the Cox regression model (0.71; 0.67–0.75). 
The calibration of both models was also comparable, indicating similar disagree-
ment between observed and predicted risks. cOnclusiOns: Using empirical data, 
we demonstrated that a prediction model developed by the novel technique of 
genetic programming has a comparable predictive ability to that of Cox regression. 
The genetic programming model was more complicated but was developed in an 
automated fashion and did not require the expertise needed for survival analysis. 
Genetic programming seems a promising technique for the automated development 
of clinical prediction models for diagnostic and prognostic purposes.
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Objectives: To develop and test a novel approach to estimate the ICER via a new 
bootstrap approach based upon the sample coefficient of variance and optimized via 
computational intelligence. MethODs: A novel bootstrap ICER estimation approach 
was developed that incorporated the sample coefficient of variance to better capture 
information within cost-effectiveness data. In this derivation, an optimal design 
value parameter was also obtained via computational intelligence. Across illustra-
tive cost and outcome correlation structures and sample sizes, a simulation study 
of 1111 replications with 999 bootstrap resamples each was conducted utilizing 
MatLab R2012b. Comparative results of point estimates versus the existing bootstrap 
method were presented as relative efficiencies, with 95% confidence intervals (CI) 
presented as coverage probability, coverage error, length, left and right bias, and 
relative bias. results: The proposed ICER yielded less statistical estimation error 
than the typical bootstrap approach across all cases, with the relative efficiency of 
point estimates ranging from +106.03% to +113.35%. An equal or improved coverage 
error for the CI was also consistently achieved, deviating from the population value 
by zero (i.e., perfect coverage) to 0.0200 versus from 0.0060 to 0.0210. Subsequently, 
an improved shortening of the CI length was noted. The relative bias suggested 
slightly more left bias and less right bias across both positive and negative cost and 
outcome correlation structures, reaching a maximum of 0.5238 for the proposed 
ICER versus 0.2222 for the usual bootstrap. cOnclusiOns: This novel method to 
estimate the ICER via the sample coefficient of variation found improvements in 
the relative efficiency of point estimators and in the coverage error and length of 
the 95% CI across all simulated cases. Irrespective of cost and outcome correlation 
structure, the relative bias of this ICER suggested a slight increase in potential left-
sided bias and decrease in right-sided bias versus the usual bootstrap.
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UsIng MUltIPle IMPUtatIon foR MIssIng valUes to IdentIfy chRonIc 
kIdney dIsease stages
Cai Y.1, Jiao X.2
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Plymouthmeeting, PA, USA
Objectives: Health care researchers often encounter missing values in many data-
sets. Ultimately, a patient record with missing fields can still carry valuable infor-
mation. This extra information becomes more important to keep in oncology and 
other rare disease studies where sample size is typically limited. The purpose of this 
study is to demonstrate that researchers can benefit from using Multiple Imputation 
(MI) approach to tackle missing value problems. MethODs: The model data from 
IMS claims (Dx) and retail prescription (Rx) contained year 2011 patient level CKD 
stage indications, longitudinal drug therapies, days of supplies, titration rates, 
Demographic characteristics, payment type, and physician specialties, etc. We built 
multivariate logistic models to identify Chronic Kidney Disease (CDK) patient stages 
using prescription data in order to further evaluate the prevalence, economic burden 
and market opportunities. Under the general assumption of missing at random 
(MAR), we used MI with regression method to impute the missing monotone and 
categorical values before the modeling process. results: The pooled results from 
5 MI imputed datasets were reported. Compared with the results from deterministic 
missing imputation approach, the MI showed larger standard error and wider 95% 
confidence interval. The wider CI reflected the additional data uncertainty from the 
missing values. CDK stage 4 (11.2%) had smallest proportion and it had lowest hit 
rate in the prediction model. MI approach showed more CDK stage 4 identifications 
than those from deterministic complete case analysis. cOnclusiOns: This study 
demonstrated that MI is capable of reflecting the underline uncertainty associated 
with the data by introducing random errors into the imputation process. MI can 
generate unbiased results and good standard error estimation when using appro-
priately. On the other hand, with the advent of modern computational technology, 
the MI becomes computationally simple and easy to use.
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strate the application of our freely available Microsoft-Excel based tool using an 
example of a network meta-analysis of anti-platelet agents in patients scheduled 
for percutaneous coronary inteventions. cOnclusiOns: Use of this freely available 
Microsoft-Excel based tool successfully demonstrated its ability to make running 
network meta-analyses more accessible to novice WinBUGS users, and facilitate 
more transparent critical appraisal of network meta-analyses.
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MatchIng wIth MUltIPle contRol gRoUPs to MaxIMIze Use of RegIstRy 
data fRoM PatIents wIth schIzoPhRenIa
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Objectives: In order to examine comparative research questions using data from a 
naturalistic, observational study (REACH-OUT) of adult patients with schizophrenia, 
non-traditional methods were needed. This abstract describes the use of multiple 
control groups to maximize inclusion of paliperidone palmitate (PP) patients in 
REACH-OUT who would otherwise be excluded from analysis due to poor propensity 
score matching with registry controls (patients receiving oral atypical antipsychotics 
(OAT)). The matched cohorts (PP and combined OAT) will be used in future resource 
use comparisons. MethODs: Because matching on propensity of PP treatment did 
not yield an adequate number of matched registry controls, a secondary set of 
OAT controls was extracted from MarketScan® claims data. PP patients unmatched 
to registry controls were matched to claims controls using a 1:1 propensity score 
matching. Post-match baseline characteristics for the PP and combined OAT cohort 
were examined using descriptive statistics. Outcomes from the claims-based control 
group will be adjusted for source bias based on 500 simulations, according to the 
Stuart-Rubin (S-R) methodology. results: Out of 354 PP with non-missing baseline 
data, 190 were matched to registry controls and the remaining 164 were matched 
to the supplemental control group. The final matched PP and OAT cohorts were 
balanced in observed attributes such as age (41.4 years vs. 42.0, p= 0.552), gender 
distribution (70.3% vs. 65.5% male, p= 0.171), ≥ 1 baseline hospitalization (29.7% vs. 
34.5%, p= 0.171), and ≥ 1 baseline ER visit (31.1% vs. 35.6%, P= 0.202), respectively. 
Initial S-R simulations suggest outcomes for the supplemented control group are 
similar to the cohort of all REACH-OUT controls (e.g., 6 month admission rates, 18.9% 
and 22.6%, respectively). cOnclusiOns: Use of multiple control groups permitted 
successful propensity score matching of all registry PP patients allowing for greater 
power, better precision, and increased external validity in the forthcoming analysis 
of the treatment effect of PP.
ReseaRch on Methods – study design
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RIsk on UsIng logIstIc RegRessIon to IllUstRate exPosURe-ResPonse 
RelatIonshIP of InfectIoUs dIsease
Ren J., Asche C., Kirkness C.S.
University of Illinois, Peoria, IL, USA
Objectives: Logistic regression is widely used to assess the likelihood of an infec-
tious disease as a function of a risk or exposure factor (and covariates), to illustrate 
the exposure-response relationship. However, because the exposure of patients 
with infectious disease is an intricate net instead of independent factors, the sta-
tistical power of logistic regression may be compromised leading to an inaccurate 
conclusion. Therefore, this study aims to examine the statistical power of logistic 
regression using simulated data of infectious disease. MethODs: A dynamic human 
immunodeficiency virus (HIV) infection was simulated among 10000 individuals 
with 1% initial prevalence and 7% target prevalence. Monte Carlo simulation method 
was used to examine the statistical powers of regular logistic regression (grouping 
sexual partners into 0-2, 3-5, 6-8, 9-11, 12-14 and ≥ 15), transformed logistic regres-
sion (using log[1+number of sexual partners]) and negative binomial regression 
on estimating the risk of HIV infection along with increasing number of unpro-
tected sexual partners. results: Regular logistic regression had poor statistical 
power and overestimated the odds ratio (OR) when the number of sex partner was 
more than 11 (power was 78% for 12-14 partners and only 4% for over 14 partners). 
Transformed logistic regression overstated the odds ratio even while the number 
of sex partner was small. Negative binomial regression had 100% power finding the 
association between HIV infection and the number of sexual partners, yet it was not 
available to provide odds ratio. cOnclusiOns: Due to the diverse distribution of 
exposure in infectious disease (negative binomial), evaluations that include logistic 
regression, to explore the exposure-response relationship, provide improved rigor 
to base decisions.
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bURden of naRcolePsy dIsease (bond) stUdy: valIdatIon of UsIng a 
sIngle dIagnosIs code to defIne PResence of an oRPhan condItIon In 
MedIcal claIMs data
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Black J.4
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Objectives: A US medical claims-based analysis was designed to evaluate bur-
den of illness associated with narcolepsy, a chronic, non-progressive disease often 
presenting early in life. Because diagnostic testing for narcolepsy is not normally 
repeated, objective evidence of a diagnosis would be absent for many patients in a 
time-limited data set. Therefore, internal validation of a study population selected 
using diagnosis codes was performed. MethODs: Within the 5-year data collec-
tion period (2006 through 2010), 9312 continuously insured adult patients were 
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(IceR) UsIng a new PeRsPectIve
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Objectives: To develop and test a new method of estimating the ICER utilizing 
the harmonic mean. MethODs: A statistically-efficient point and 95% confidence 
interval (CI) estimator of the ICER was derived that utilized the harmonic mean of 
costs and effects, hence applying the inverse of the mean of the inverses for use 
in statistical summarization. An additional correction factor developed through 
computational intelligence was also incorporated to capture existing information 
from the usual bootstrap ICER estimator. A simulation study of 1111 replications 
with 999 bootstrap resamples each utilizing Matlab R2012b was undertaken across 
illustrative positive and negative correlation structures of costs and outcomes for 
varying sample sizes of treatment and referent groups. Results were presented as 
relative efficiencies for point estimators, while coverage probability, coverage error, 
length, left and right bias, and relative bias were presented for the 95% CI. results: 
Compared to the usual bootstrap approach, optimal methods based upon the har-
monic mean yielded point estimates with greater relative efficiency across all ana-
lytic scenarios, ranging from 103.22% to 111.03%. The 95% CI coverage error was 
also consistently lower, deviating from the population value by 0.0005 to 0.0257 
versus the usual bootstrap range of 0.0031 to 0.0302. Thus, an improved shortening 
of the CI length was found across all cases. The maximum relative bias of the new 
estimator was 0.7714 versus 0.2703, which reflected a somewhat higher left bias 
and lower right bias among positive correlation structures, and a greater right bias 
and lesser left bias among negative correlation structures. cOnclusiOns: The new 
approach to estimate the ICER that utilized the harmonic mean allowed for more 
statistically-efficient point estimation. The 95% CIs presented with less coverage 
error and shorter lengths, though typically at the cost of a potential increase in 
relative bias.
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sURvIval cRossoveR adjUstMent and cost effectIveness analysIs: an 
eMPIRIcal and MethodologIcal RevIew wIth aPPlIcatIon
Hopkins R.B.1, Campbell K.1, Burke N.1, Levine M.1, Thabane L.1, Duong M.2, Shum D.2,  
Goeree R.1
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Canada
Objectives: First, to summarize the methodological literature on the correction 
of overall survival for the impact of crossover. Second, to examine and compare 
the use of these statistical methods in cost-effectiveness analyses (CEAs). Third, 
to apply recommended statistical methods to correct overall survival in a clini-
cal trial that included crossover. MethODs: Medline, Embase, NHSEED and HEED 
databases, along with grey literature were searched for methodological evidence 
on the appropriate use of survival adjustment, including but not limited to, Inverse 
Probability of Censor Weighting (IPCW) and Rank Preserving Structural Failure Time 
Modelling (RPSFT). In addition, empirical CEAs that applied survival adjustment 
were identified and reviewed. The appropriate methods were applied to a trial with 
crossover to compare IPCW, RPSFT, intention to treat (ITT) and per protocol (PP) 
analysis. results: The choice of IPCW or RPSFT depends on six factors: common 
treatment effect, true treatment effect, crossover percentage, disease severity, time 
dependence of treatment effect, and crossover mechanism. Nine placebo-controlled 
CEAs that applied survival adjustment were identified: two studies used one method 
without comparison, one study incorporated censor weighting for a meta-analysis, 
five studies reported one method and compared to either ITT or PP analysis, one 
as the primary analysis and four as sensitivity analysis. Only one study reported 
a comparison of multiple methods, IPCW and RPSFT. Empirically, PP, RPSFT and 
IPCW produce lower hazard ratios than ITT. Ranking of PP, RPSFT and IPCW varied 
by the factors. None of the six factors were discussed thoroughly in the empirical 
results. Based on the trial, all patients that crossed-over survived which violates the 
assumptions of common treatment effect for RPSFT and different disease severity 
for IPCW and RPSFT. cOnclusiOns: Applying the six factors guides the a priori 
assessment of appropriate choice of crossover method. In this case, neither IPCW 
or RPSFT were appropriate.
PRM123
a MIcRosoft-excel based tool foR RUnnIng and cRItIcally aPPRaIsIng 
sIMPle netwoRk Meta-analyses UsIng wInbUgs – an oveRvIew and 
aPPlIcatIon
Brown S.T.1, Cameron C.2, Grima D.T.1, Wells G.3
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Canada, 3University of Ottawa Heart Institute, Ottawa, ON, Canada
Objectives: The role of network meta-analyses has increased dramatically in 
recent years. WinBUGS has been the most widely used software to conduct net-
work meta-analyses. However, the learning curve for using WinBUGS to conduct 
network meta-analyses successfully can be daunting, especially for new users. 
Further, critically appraising network meta-analyses conducted in WinBUGS is chal-
lenging given the limited data analysis and graphical output fromWinBUGS, thus 
network meta-analyses often rely on different software packages. The objective is 
to develop a tool which 1.) makes running network meta-analyses more accessible 
to novice WinBUGS users; and 2.) facilitates a more transparent and efficient critical 
appraisal of network meta-analyses. MethODs: We developed a freely available 
Microsoft-Excel based tool, programmed in Visual Basic for applications within 
Excel, which provides an interface for conducting a network meta-analysis using 
WinBUGS from within Microsoft Excel. This tool allows the user to modify assump-
tions and to run the network meta-analysis, and results are returned to an Excel 
spreadsheet. The tool displays the data, evidence networks, forest plots, rankograms, 
and inconsistency plots all entirely within Microsoft Excel. results: We demon-
